ADC Contract Manufacturing Market Report 2026 (7Th Edition) Commercial Scale Dominates ADC Manufacturing With 90% Market Share A Clear Analysis Of Market Trends, Drivers, Challenges, And Opportunities

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "ADC Contract Manufacturing Market (7th Edition): Distribution by Stage of Development, Process Component, Type of Payload, Antibody Isotype, Target Indication, Antibody Origin, Type of Linker, and Key Geographical Regions - Industry Trends and Forecast 2025-2035" has been added to ResearchAndMarkets's offering.

The ADC contract manufacturing market is projected to grow from USD 2.13 billion to USD 3.21 billion by 2035, reflecting a CAGR of 4.6%. Antibody drug conjugates (ADCs) are increasingly becoming pivotal in cancer treatments, thanks to their stability, specificity, and tumor selectivity. The current pipeline features over 614 clinical candidates and 28 approved ADC programs. As production processes are complex and resource-intensive, many developers are outsourcing to ADC contract manufacturers, which is expected to drive market expansion during the forecast period.

Market Dynamics

With 35 companies specializing in ADC manufacturing globally, the majority offer comprehensive services, addressing challenges like technological transfers and scale-ups. Continuous upgrades in capabilities by stakeholders offer a competitive edge, supported by rising partnerships-60% forged in the last three years. Over 780 clinical trials for ADCs are underway, highlighting the expanding focus on safe and effective cancer treatments. Much of this momentum is concentrated in North America, underscoring its advanced manufacturing infrastructure. The projected growth in ADC therapeutics will further escalate demand for outsourcing manufacturing services.

Regional and Segment Insights:

• Europe currently leads, covering 45% of the ADC contract manufacturing market, followed by North America. However, the market in North America is set to capture significant growth by 2035, with around 85% of companies providing manufacturing services.
• The commercial scale occupies nearly 90% of the market, driven by high ADC demand as targeted cancer therapies. The clinical scale is expected to grow at a CAGR of 7.6%.
• Solid tumors dominate the ADC market, claiming about 80% share due to numerous therapies in trials. Meanwhile, hematologic cancers are anticipated to expand at an 8.7% CAGR.
• Antibodies remain the focal point owing to their intricate engineering demands, securing the highest market share through 2035.
• Asia-Pacific is poised for growth at an 8.5% CAGR due to cost advantages in regions like China and India. Key players include Shilpa Biologics, WuXi Biologics, and Samsung Biologics.

Industry Key Players

Leading companies: AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma, MabPlex, Millipore Sigma, Lonza, WuXi Biologics.

Research Insights:

• The report offers comprehensive analysis on market segments by development stage, payload type, antibody origin, and geographical regions.
• Insights into partnerships, capacity analysis, and regional capability assessments are detailed to guide strategic decisions.
• In-depth evaluations of clinical trials and potential strategic partnerships with ADC developers are included.

Report Utility:

• This report serves as a critical resource for understanding the market dynamics and competitive landscape, offering revenue projections and identifying growth opportunities.
• It aids stakeholders in making informed decisions by providing a clear analysis of market trends, drivers, challenges, and opportunities.
• The report is complemented with analytics, enhanced customization options, and updates, ensuring its relevance and utility over time.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01042026004107003653ID1110929261